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In this study specific high affinity binding sites for atria1 natriuretic factor (rANF(99-126)) have been identified on cultured endothelial cells of 
bovine pulmonary artery origin (BPAEC). A time-dependent rise in cellular cGMP levels stimulated by rANF(99-126) was followed by release 
of the nucleotide into the incubation medium. The use of truncated, ring-deleted and linear atria1 peptide analogs in competitive displacement 
analysis and measurement of cGMP accumulation indicated that only a minor proportion (5-l 1%) of the available receptor pool was of the ANF-B 
receptor subtype, linked to guanylate cyclase, with the remaining major proportion possibly of the ANF-C (clearance) receptor subtype. The ex- 
istence of two ANF receptor subtypes in this cell culture model would suggest a significant role for the circulating peptide in modulation of pulmo- 
nary endothelial cell function, which would influence or complement i s direct actions on the underlying vasculature of the pulmonary circulation. 
ANF receptor subtype; Endothelial cell; Pulmonary artery 
1. INTRODUCTION 
Atria1 natriuretic factor (ANF) is known to influence 
cardiovascular homeostasis by inducing natriuresis, 
diuresis and relaxation of vascular smooth muscle 
[l-3], and as its name suggests, this peptide is primarily 
synthesised in, stored and secreted from mammalian 
atria. However, ANF has been detected in low amounts 
in several other tissues [4-61 and more recently 
evidence has been provided that the lungs may be 
capable of ANF synthesis, in particular during the 
development of cardiac dysfunction [7]. Moreover, 
ANF receptors have been purified from bovine lung 
homogenates [8] and experimental studies using 
isolated arterial and venous preparations have 
demonstrated that ANF can induce relaxation of the 
pulmonary vasculature [9, lo]. Furthermore, there is 
evidence that this relaxant effect of ANF is impaired in 
primary pulmonary hypertension [l 11, and in 
pulmonary artery hypertension elevated ANF levels 
have been reported in the pulmonary circulation [ 121. 
number of vasoactive agents [ 131, the functional conse- 
quences of ANF receptor activation in such cells are a 
matter for speculation. 
We report below on the identification of specific, 
high affinity binding sites for ANF in cultured BPAEC 
and we conclude that there are at least two ANF recep- 
tor subtypes present in this system, one of which, the 
ANF-B receptor (present as the minor component) is 
linked to guanylate cyclase. We further suggest hat the 
so-called ANF-C or clearance receptor which forms the 
major part of the total receptor pool may be responsi- 
ble for a time-dependent internalization of ANF 
observed in these cells. Finally we demonstrate that 
ANF appears to produce cGMP in BPAEC for subse- 
quent export, since a time-dependent efflux of the 
nucleotide occurred following challenge with the 
peptide. 
2. MATERIALS AND METHODS 
In this study we decided to evaluate the importance 
of pulmonary vascular endothelium in the actions of 
ANF since in general, vascular endothelium constitutes 
the first target ‘organ’ seen by circulating atria1 pep- 
tides. The model system which we chose was a primary 
culture of bovine pulmonary artery endothelial cells 
(BPAEC). While endothelial cells are known to 
modulate the responses of isolated blood vessels to a 
[‘2sI]rANF(99-126) and [‘*sI]NaI (carrier free) both approx. 
2000 Ci/mmol were purchased from Amersham. Synthetic peptides 
rANF(99-126), rANF(lOl-126), rANF(103-123) and rANF 
(103-125) were obtained from Sigma. A ring-deleted analog 
des[Gln1’6,Ser”7,Gly”8,Leu”g,Gly’20]ANF102-121-NH~ (C-ANF) 
and Tyr”%ANF(103-125) were obtained from Peninsula 
Laboratories. The peptides des[Cys ‘oS,Cys’Z1]rANF104-126 
(#$C-46313), and des[PhelO6,Gly107,Alal15,Gln116]ANF103-126 
(#SC-46542) were a gift from Dr E.H. Blame. Anti-cGMP serum 
was obtained from Immunotech, France. All other chemicals were of 
the highest purity commercially available. 
Correspondence address: A.K. Keenan, Department of Phar- 
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2.1. Cell culture 
Bovine pulmonary artery endothelial cells (BPAEC), a primary ceil 
line, were obtained from the University of Miami. The cells were 
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maintained in DMEM containing 5% foetal calf serum, 5% Nu- 
serum, 50 units/ml of penicillin, 50pg/ml of streptomycin, 
2.5 &ml fungizone and 2 mM glutamine at 37°C in a 5% 
COz/humidified incubator. Subcultures were made by passaging con- 
fluent cells (which displayed typical cobblestone morphology) with a 
trypsin (O.S%)/EDTA (0.2%) mixture in Hank’s balanced salt solu- 
tion (HBSS). Typically, passages 1 l-24 of these cells were used in ex- 
periments. 
2.2. Iodination of cGMP 
lodination of succinyl cyclic GMP tyrosine methyl ester was per- 
formed as described by Cailla et al. [14] and the monoiodinated 
derivative was purified on Sephadex G25. The ability of the antibody 
to bind the derivative in eluted fractions was tested and those with the 
greatest affinity for antibody were pooled and used in assays. 
2.3. Binding studies 
All binding assays were performed in 24-well plates (Nunclon) 
(seeding density approximately 100000 cells/well). Prior to incuba- 
tions with [‘251]rANF(99-126), cell monolayers were washed twice 
with 1 ml assay buffer (HBSS containing 2 mg/ml bovine serum 
albumin) at 37°C. Various concentrations (0.05-3.0 nM) of 
[‘251]rANF(99-126) in assay buffer (spec. act. -450 cpm/fmol) were 
added to the wells and the plates were placed in a COz/humidified in- 
cubator at 37°C for 30 min. Cells in parallel wells were exposed to 
identical concentrations of [‘2SI]rANF(99-126) but with lOO-fold 
molar excess of unlabelled rANF(99-126) added, to determine 
nonspecific binding. Following the binding reaction, the cells were 
immediately washed (4 x 1 ml) with ice-cold assay buffer. Cell 
monolayers were then treated with 700~1 1 M NaOH at 37’C for 
IO min and bound radioactivity was determined using an LKB 
Universal Gamma counter. Alternatively, 200 $/well of trypsin- 
EDTA mixture in HBSS was added to dissociate cells for counting on 
a haemocytometer. For competitive displacement experiments 
0.5 nM [“sI]rANF(99-126) was added to the wells alone or in the 
presence of increasing concentrations (1 nM-1 PM) of unlabelled 
rANF(99-126), rANF(l03-125), #SC-46313, #SC-46542, C-ANF 
or rANF(l03-123). The cells were then incubated and treated as 
above. 
For receptor internalization studies 0.5 nM [‘251]rANF(99-126) 
was added to the wells and the cells were incubated at either 37°C or 
4°C for the times indicated. The cells were washed (4 x 1 ml) with 
ice-cold assay buffer and treated either directly with 700,ul 1 M 
NaOH as above to determine cell-bound radioactivity, or after ‘acid- 
stripping’ with 0.2 M acetic acid pH 2.5, containing 0.5 M NaCl for 
6 min at 4°C to remove surface-bound radioactivity (method of 
Haigler et al. [15]). 
2.4. Intracellular cGMP measurement 
Endothelial cells subcultured in 24-well plates were used. Cell 
monolayers were first washed (as described above), then prein- 
cubated with assay buffer containing 0.5 mM isobutylmethylxan- 
thine (IBMX) for 15 min at 37°C prior to the addition of ANF or its 
analogs. Following incubation of cells with peptide for the specified 
times, reactions were stopped by aspiration and samples were then 
processed in either of two ways: (i) 600 ~1 10% (w/v) trichloroacetic 
acid (TCA) was added to each well and samples were extracted with 
water-saturated ether (4 x 4 ml) and evaporated to dryness; (ii) wells 
were treated with 300 pl 0.1 M HCl for 1 h. The amounts of cGMP 
were quantitated by radioimmunoassay after acetylation, using stan- 
dard procedures [16]. 
2.5. Extracelhlar cGMP measurement 
At an appropriate time at 250 ~1 aliquot of incubation medium was 
taken and treated as described by Schini et al. [17]. Briefly, the sam- 
ple was extracted with 1.2 M HC104 and neutralized with KOH 
before acetylation and radioimmunoassay. 
2.6. Data analysis 
ANF binding data were analysed using the LIGAND computer 
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programme [18] and significance levels were determined using a 
paired Student’s t-test. 
3. RESULTS AND DISCUSSION 
The binding of [1251]rANF(99-126) to BPAEC was 
saturable, as can be seen in Fig. 1 and Scatchard 
analysis of the binding data using a one-site model 
(Fig. 1, inset) indicated the presence of a single class of 
high affinity binding site for rANF(99-126): & and 
B,, values were respectively 0.62 f 0.08 nM and 102 
+ 20 fmol/106 cells, corresponding to 52400 sites/cell. 
Similar & values have been reported for other tissues 
such as rabbit lung membranes [19], bovine aortic en- 
dothelial cells and vascular smooth muscle cells [20]. 
While fitting of a two site model to the binding data 
generated with rANF(99-126) was not significantly 
better than the single site model, the existence of recep- 
tor subtypes is however suggested by the experiments 
described below. 
Binding of [“‘I]rANF(99-126) was displaced by 
unlabelled rANF(99- 126), rANF(103-125), 
#SC-46313, #SC-46542, C-ANF and rANF(103-123) 
in a dose-dependent manner (Fig. 2), and the com- 
parable ICSO values (the concentration of peptide re- 
quired to displace 50% of the radioligand binding) are 
shown in Table I. However, in contrast to 
rANF(99-126) and rANF(103-125), #SC-46313, 
#SC-46542, C-ANF and rANF(103-123) appeared to 
incompletely displace [1251]rANF(99-126) binding, 
even at a concentration of 1 PM. The results indicate 
that # SC-463 13, # SC-46542, C-ANF and 
rANF(103-123) failed to displace 5070, ll%, 7.8% and 
6.5% of binding respectively. A more detailed ex- 
amination (using an increased number of replicate 
measurements) of the extent of residual rANF(99-126) 
binding in the presence of saturating concentrations of 
#SC-46313, #SC-46542, C-ANF and rANF(103-123) 
was thus undertaken. The results shown in Table I in- 
dicate that each of these ligands displaced significantly 
less [‘2’I]rANF(99-126) than rANF(99-126) at the 
same concentration. Furthermore, analysis of the in- 
hibition curves (Fig. 2) using the LIGAND program 
showed that the data best fitted a one site model i.e., 
the incomplete displacement is not explained in terms 
of varying affinity states of the individual ligands for 
receptor subpopulations. In summary therefore, 
although all peptides studied bind with comparable af- 
finity, rANF(103-125), #SC-46313, #SC-46542, C- 
ANF and rANF(103-123) apparently fail to recognise 
a small proportion of the ANF receptor pool in 
BPAEC. To further quantify binding of rANF(99-126) 
to these remaining sites, the displacement of 
[‘*‘I]rANF(99- 126) by unlabelled rANF(99- 126) was 
carried out in the presence of an excess of #SC-46542 
and #SC-463 13. Based on the initial displacement ex- 
periments, a concentration of 1 PM #SC-46542 or 
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1’ 25 I]rANF(99-126) ] nM 
Fig. 1. Saturable binding of [**sI]rANF(99-126) to cultured BPAEC. 
means -I SE from 4 experiments performed in duplicate. 
Confluent cells were incubated at 37°C for 30 min with the indicated 
concentrations of [‘“‘I]rANF(99-126). Nonspecific binding (solid 
diamond), determined in the presence of a lOO-fold molar excess of 
unlabelled rANF(99-126), was 5-20010 of the total binding (open 
boxes). Specific binding (solid boxes). Data points represent mean 
values from a representative xperiment performed in duplicate. 
(Inset) Scatchard plot of binding data. Kd and B,., values given are 
# SC-463 13 was chosen 
radioligand from at least 
Under these conditions, ___ 
which would displace the 
90% of the binding sites. 
rANF(99- 126) completely 
displaced residual [ ‘?]rANF(99- 126) binding (Fig. 3). 
The 1% for rANF(99-126) was similar in the absence 
or presence of 1 pM unlabelled #SC-46542 or 
#SC-46313 (0.4 nM, compared to 0.63 nM and 
0.2 nM). This would suggest hat rANF(99-126) binds 
to both classes of binding sites with the same affinity 
and is nonselective, whereas # SC-46542 and 
#SC-46313 bind to the major subset (90’7o/92%) of 
ANF binding sites. The ability of atria1 peptides to in- 
duce cGMP accumulation was next investigated and 
Fig. 4 shows the time-course profile obtained for intra- 
and extracellular cGMP accumulation in BPAEC 
stimulated with 0.1 PM rANF(99-126). A similar pro- 
file was obtained for rANF(103-125) (data not shown). 
Intracellular cGMP levels were maximised l-5 min 
after exposure of the cells to peptide, thereafter 
decreasing but still remaining elevated above basal after 
2 h. While the effects of raised intracellular cGMP 
levels on endothelial cell function are not as yet 
established, it has been proposed that this nucleotide 
60 _ 
0 rANF(103.125) 
0 (#SC-4631 3) 
-. (1X-46542) 
9 C-ANF(102-121) 
9 rANF(103.123) 
0 10 6 6 4 
_ Log [peptide] 
Fig. 2. Competitive displacement of [iZ51]rANF(99-126) binding by 
varying concentrations of unlabelled atria1 peptides; see inset for key. 
respectively. 
[‘2SI]rANF(99-126) (0.5 nM) was incubated with confluent 
monolayers of BPAEC in 24-well multiwell plates and various 
concentrations of unlabelled analogs. Specific binding data shown 
were calculated as total binding minus non-specific binding (in the 
presence of 1 FM unlabelled rANF(99-126)). Data points represent 
the mean of at least 2 individual experiments, performed in duplicate. 
For the sake of clarity, standard errors were omitted from the figure 
but were < 10% of control except for those at 1 x 10e9, 5 x 10m9 and 
1 x lo-* M rANF(103-123), which were 12.9%, 14.7% and 12.9%, 
Table I 
Binding 
ICSO (nM) 
rANF99- 126 0.4 0.10 
rANFlOl-126 n.d. 0.10 
rANF103-125 0.84 3.00 
Tyr’06ANF103-125 n.d. 5.00 
rANF103-123 4.3 >lOcQ 
C-ANF102-121 4.95 >lOOO 
(#SC-46313) 0.42 >lOOO 
(#SC-46542) 3.28 >lOoO 
Intracellular 
cGMP accumul- 
ation 
EC50 (nM) 
Vo Total 
binding 
1 FM peptide 
8.9 i 1.5 
_ 
- 
17.3 + 2.5** 
14.6 f 3.2* 
16.8 + 1.2** 
21.5 f 4.8** 
I& values (i.e. the concentration of peptide required to displace 
50% of the radioligand binding) and EC50 values (i.e. the 
concentration of peptide required to produce half-maximal cGMP 
accumulation relative to the maximal standard response obtainable 
with 1 /tM rANF(99-126)) for the atria1 peptide analogs used. n 2 3 
in each case. (n.d. = not determined); Vo total binding in the presence 
of 1 PM displacer. Comparisons of residual [‘251]rANF(99126) 
binding (cpm) were made between rANF(99-126) and (i) 
#SC-46313, (ii) #SC-46542, (iii) C-ANF and (iv) rANF(103-123) 
and differences were significant at the * P < 0.025 and l * P < 0.005 
level in each case; data from at least four separate xperiments each 
performed in triplicate 
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-W#SC-46542 
f rANF(99-126) 
4 rANF(99-126) + #SC-46542 (1pt.i) 
120 
1 
oxsc-46313 
+ rANF(99-126) 
+ rANF(99-126) + #SC-46313 (1pM) 
0 10 8 6 4 0 10 6 6 4 
- Log [peptide] - Log [peptide] 
Fig. 3. Competition for [1251]rANF(99-126) binding to BPAEC by rANF(99-126), #SC-46542 (a), #SC-46313 (b), and rANF(99-126) in the 
presence of 1 ,uM #SC-46542 (a) or #SC-46313 (b). See insets for key. Binding data were corrected for non-specific binding as detailed in the 
legend to Fig. 2. The data presented are means of duplicate determinations from one experiment which was repeated three times with similar 
results. Standard deviations are not shown but were <5% of control except for those at 1 x 10T8 M #SC-46542 and 1 x lo-’ M #SC-46313 
which were 7.7% and 9.050/o, respectively. 
can exert a cytoprotective ffect by antagonising the ac- 
tions of agents known to increase endothelial cell 
permeability [21]. rANF(99-126)~stimulated produc- 
tion of cellular cGMP was followed by a time- 
dependent release of the nucleotide into the incubation 
medium. This release was not significant at short in- 
cubation times (when cellular cGMP content peaked), 
but thereafter increased steadily for up to 2 h. 
The association of ANF-stimulated cellular cGMP 
accumulation with a subsequent time-dependent release 
of nucleotide into the extracellular medium has been 
reported in a number of cell types including mam- 
malian erythrocytes [22], glial cells [23], fibroblasts 
[24], bovine aortic endothelial cells and smooth muscle 
cells [25]. The role of this released cGMP is not known 
at present although it is possible that it is merely expell- 
ed as part of a mechanism to control cellular nucleotide 
content. Alternatively however, this released cGMP 
may somehow itself gain access to the smooth muscle 
and thereby contribute to vascular relaxation. 
In order to compare the ability of ANF and its 
analogs to stimulate intracellular cGMP accumulation, 
a series of dose-response relationships was established. 
The order of potency for the peptides was 
rANF(99-126) > rANF(lOl-126) > rANF(103-125) > 
Tyr’*%ANF(103-125) >>>> C-ANF, with 
#SC-46313, #SC-46542 and ‘rANF(103-123) giving 
160 
no perceptible increase in intracellular cGMP levels 
above basal (Fig, 5). The relevant EC50 values are given 
in Table I. In addition #SC-46542 and #SC-46313 do 
not appear to be competitive antagonists at the ANF-B 
20 -I T 
*.,.,.,.,.,.,., 
0 20 40 60 80 100 120 140 
Time (min) 
Fig. 4. Time-course profile for intracellular (open symbols) and 
extracellular (solid symbols) cGMP accumulation in BPAEC 
stimulated with rANF(99-126). Each data point represents the 
mean * SE of three determinations (stimulated - basal). Cells were 
washed as described in section 2 and incubated for 15 min with 
0.5 mM IBMX in assay buffer before the addition of 0.1 pM 
rANF(99-126) (final cont.). At the specified times an aliquot of 
incubation medium was taken (for measurement of extracellular 
cGMP) and the reaction was stopped by aspiration. The cells were 
treated with either TCA or HCl for extraction of cellular cGMP. In 
both cases the cGMP was quantitated by radioimmunoassay. 
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10 
8 
6 
1 -m- rANF(99-126) 
2* rANF(lOl-126) 
3-w rAfjFd$03-125) 
49 Tyr rANF (103-12: 
5-c C-ANF(102-121) 
6 0 (#SC-46542) 
7 + (#SC-4631 3) 
8a rANF(103-123) 
I I I I 
9 8 7 6 
- Log [peptide] 
Fig. 5. Dose-response curves for intracellular cGMP accumulation stimulated by the indicated atria1 peptides (see inset). Data points represent 
mean f SE of three determinations. Cells were preincubated with 0.5 mM IBMX and then with the specified peptide concentrations for 5 min 
at 37°C. Reactions were stopped by aspiration and cGMP extracted as described in section 2. Basal cGMP accumulation: 1.55 f 0.15 pmol 
cGMP/106 cells/min (n = 10). 
receptor since neither of the two analogs affected the 
log dose-response curve for cGMP accumulation by 
rANF(99-126) (data not shown). Basal accumulation 
of cGMP in these_ cells was 1.55 + 0.15 pmol/106 
loo _ 
60 - 
20 - 
O_ 
I 1 1 1 I 
0 100 200 300 400 
Time (min) 
Fig. 6. Time-course for [‘251]rANF(99-126) internalization in 
BPAEC at 37°C and 4°C. Results are expressed as the % of cell- 
bound radioactivity at each time point which remained following 
‘acid-stripping’. Each point represents the mean f SE of two separate 
experiments performed in duplicate. 
cells/min. The magnitude of the ANF-stimulated in- 
creases varied considerably between different cell bat- 
ches but was reproducible within a given batch. In 
contrast to previous reports of maximal increases in 
bovine [17] and porcine [26] aortic endothelial cells 
(160- and 142-fold respectively), the stimulations ob- 
tained here are relatively small, maximal increases over 
basal being 9-12-fold. However, basal cGMP ac- 
cumulation in BPAEC appears to be relatively high 
which may reflect a greater metabolic activity of this 
tissue. 
To summarise the cGMP data therefore, it appears 
that those ligands which are selective for the major 
subset of binding sites are also devoid of guanylate 
cyclase stimulant activity. This selectivity has previous- 
ly been reported for #SC-46313 in rabbit lung mem- 
branes [27]. Furthermore, the ring-deleted analog 
C-ANF which produced only a slight increase in cGMP 
accumulation (-Zfold at 1 ,uM, see Fig. 5) has been 
shown to be selective for the ANF-C, or clearance 
receptor in the kidney and to mediate the sequestration 
and metabolic clearance of ANF in this organ [28]. It 
is possible therefore that the major subset of ANF bin- 
ding sites in BPAEC are ANF-C receptors and that the 
pulmonary circulation serves an important clearance 
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function for ANF. Indeed it has been shown in a study 
involving human subjects that the lung clears more 
ANF than other tissues such as liver or kidney [29]. In 
support of such a function, we observed a time- and 
temperature-dependent internalization of [“‘I]rANF 
(99-126) in these cells (Fig. 6), with up to 84% of the 
cell bound radioactivity located in an acid-resistant (in- 
tracellular) compartment after 6 h at 37°C. The overall 
significance of the lung in ANF action is also supported 
by the observation that this organ is an important 
source of the peptide (stored as the 126 amino-acid pro- 
hormone) in experimental cardiomyopathy [7]. 
In conclusion therefore, this study demonstrates for 
the first time that vascular endothelial cells from the 
pulmonary circulation express two ANF receptor sub- 
types. We suggest hat interaction of the peptide with 
both of these receptors may be of primary importance 
in the actions of ANF in the lung. 
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